Premium
What is expected in lung function after lung transplantation due to end‐stage pulmonary silicosis?
Author(s) -
SidneyFilho Luzielio Alves,
Watte Guilherme,
Santos Pedro Augusto Reck,
Marcelo Schio Sadi,
Camargo Spencer Marcantonio,
Perin Fabíola Adélia,
Hochhegger Bruno,
Felicetti Jose Carlos,
Camargo Jose de Jesus Peixoto,
Moreira Jose da Silva
Publication year - 2017
Publication title -
clinical transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 76
eISSN - 1399-0012
pISSN - 0902-0063
DOI - 10.1111/ctr.13105
Subject(s) - medicine , silicosis , dlco , spirometry , pulmonary function testing , lung transplantation , confidence interval , population , stage (stratigraphy) , lung , surgery , lung function , diffusing capacity , pathology , paleontology , environmental health , asthma , biology
Abstract In this study, we aimed to determine the impact of lung transplantation ( LT x) on pulmonary function tests ( PFT s) and survival among patients with end‐stage silicosis. We included patients with end‐stage silicosis on the wait list for LT x, between January 1989 and July 2015 (N = 26). Sixteen of these patients received LT x; 10 were eligible, but did not undergo LT x (non‐ LT x) during the study period. Retrospective information on PFT s (spirometry [volumes and flows], 6‐minute walking test [6 MWT ], and DLCO ) was retrieved from patients’ medical charts, including baseline information for all patients and follow‐up information for the LT x. At baseline, most patients presented with spirometric and 6 MWT values that were suggestive of severe disease ( FEV 1 / FVC 76.5 ± 29.7; 6 MWT 267.4 ± 104.5 m). Significant increases in these values were observed at follow‐up in the LT x ( P = .036 and .151, respectively). The overall median survival of patients in the LT x and non‐ LT x was 3.35 years (95% CI : 0.16‐14.38) and 0.78 years (95% confidence interval [ CI ]: 0.12‐3.65) ( P = 0.002), respectively. For patients with end‐stage silicosis, LT x offers significant benefits regarding pulmonary function and survival when compared to non‐ LT x, and is a reliable tool to help this critical population of patients, whose only treatment option is LT x.